WHO approves Novavax and COVAXIN
Novavax is a traditional vaccine that does not transfect cells. It has the potential for a superior safety profile relative to the existing mRNA vaccines. So does COVAXIN.
ICYMI: On December 17, the WHO has granted the Novavax vaccine Emergency Use Approval.
The Novavax vaccine was granted emergency use authorization in November in Indonesia, the first country to do so, and was soon followed by the Philippines. The company has also filed with the U.K. and the European Medicines Agency, with plans to apply to the U.S. Food and Drug Administration before the end of this year.
This is good news because this vaccine is a “traditional” vaccine that does not transfect your existing cells, so it “should” have a much better safety profile than any of the three vaccines now available in the US for two major reasons:
No transfection. All of the existing vaccines basically invade your cells and them to express a spike protein; your immune system may then start attacking your own organs and kill you as explained here. This doesn’t happen with Novavax because you are injected with the antigen.
A controlled amount of antigen. The other major safety benefit is that a controlled amount of antigen is injected. With the mRNA vaccines, the amount of antigen that is ultimately expressed is a complete crap shoot.
Does this mean that Novavax is “safe.” No, it just means it has the potential to be safer assuming they didn’t screw up anything else. And even if they got everything right, simply injecting particles with the spike protein could be dangerous. In short, it’s possible that there may not be a safe vaccine for this virus.
Certainly Dr. Richard Fleming doesn’t think the Novavax vaccine is safe. One of my followers wrote: “it’s viral like particles (spikes) adhered to plastic inner core, mixed with proprietary saponin adjuvant called Matrix M1.”
Are you feeling lucky?
However, I seriously doubt the FDA will approve it for use in the US since it would take away market share from the other manufacturers
The FDA doesn’t approve things based on science or safety anymore. Those days are gone.
If this vaccine were approved in the US, everyone in the US would want it and avoid the other three existing vaccines like the plague. Their market share would drop to zero. So it isn’t going to be available here. The FDA will make up a reason it isn’t safe. So it will not be accepted in the US (e.g., for satisfying the unethical vaccine mandates) even if it works just as well as the other vaccines. Mandates are not about safety; they are about forcing compliance with what the government wants you to do.
The good news is that other parts of the world will have a safer alternative which is better than what they have now. So in that sense, this is “good news.”
COVAXIN approved on November 3, 2021
COVAXIN is another traditional vaccine that was approved by the WHO on November 3, 2021. Many people believe it is a safer option than any of the alternatives.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen.
More on Novavax and Covax-19
See this excellent article for more about protein-based vaccines.
What I would do today: avoid all of them
If I were forced to make a choice of vaccine today, and COVAXIN and Novavax were among the options, I would definitely look at the current evidence and make a choice.
However, if I weren’t forced to choose a COVID vaccine now, I would still refuse to be vaccinated because COVID isn’t deadly or dangerous if you know how to recognize and treat it.
Only after the safety profile is well established in large populations, would I even consider it. I’d look carefully at risk-benefit analyses. I’ve learned my lesson never to trust the regulatory agencies and drug companies again.
“In VAERS we trust.”
Novavax/Covovax is NOT a conventional vaccine, no matter who says so!
"NVX-CoV2373 has been described as both a protein subunit vaccine and a virus-like particle vaccine, though the producers call it a "recombinant nanoparti-cle vaccine".
The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The spike protein was modified by incorporating two proline amino acids in order to stabilize the pre-fusion form of the protein; this same 2P modification is being used in several other COVID-19 vaccines. The baculovirus is made to infect a culture of Sf9 moth cells, which then create the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a syn-thetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike pro-teins."
There is also the traditional vaccine developed by Dr Petrovsky and his team in South Australia, called Covax-19, but due to contracts with the big 4, the Australian govt. won't allow or approve it.